Ness, Gregory M DDS

Ohio State researchers developed a method using electricity to permanently stabilize PVC, reducing microplastic shedding and offering a potential solution to plastic pollution.

Telehealth-delivered cognitive behavior therapy reduces suicide attempts and thoughts, outperforming present-centered therapy in a study published in JAMA Network Open. This shift to virtual therapy, prompted by COVID-19, expands access to effective treatments, especially in rural areas.

The Lupus Foundation of America honors Dr. Brad H. Rovin with the 2024 Evelyn V. Hess Award for his research on lupus nephritis, and Dr. Alí Duarte-García with the 2024 Mary Betty Stevens Young Investigator Prize for his contributions to lupus research.

Pharma industry sponsors dominate clinical cancer research, enrolling over eight times more patients than federally sponsored trials. This shift, which has dramatically increased over decades, benefits drug discovery but skews research priorities towards new drug approvals. Federally-funded trials address broader research questions and show higher demographic diversity. The influx of pharma-sponsored research raises concerns about potential bias in reported drug efficacy.

Y-mAbs Therapeutics reported Q3 2024 net revenue of $18.5 million, a 10% decrease from Q3 2023, attributed to reduced product revenues and prior licensing revenue. Despite this, net revenue for the first nine months of 2024 remained stable at $61.2 million. The FDA-approved therapy DANYELZA saw a 5% drop in U.S. product revenues, influenced by Medicaid claim adjustments and increased competition. Y-mAbs maintained its full-year revenue guidance of $87-95 million, expecting to fall in the lower half of the range, and emphasized its strategic focus on drug development, including advancements in its SADA PRIT technology platform and a new licensing agreement for potential commercialization in Japan.

A new nickel-based chemical complex stabilizes alkyl cross-coupling reactions, enabling reliable synthesis of 3D drug molecules from inexpensive materials, potentially accelerating pharmaceutical discovery.

Out-of-pocket costs for MS, Parkinson's, and Alzheimer's meds have sharply increased, with MS patients seeing costs more than triple from 2012 to 2021. Despite generics reducing drug costs by 48% to 80%, high deductibles and co-pays limit patient savings, impacting care and health.

A study shows a 37% reduction in opioid-meth overdose deaths due to expanded access to addiction treatment and naloxone. Communities with increased access had 8.9 deaths per 100,000, compared to 14.1 in those without. The study, part of the HEALing Communities Study, adjusted its education efforts to emphasize the threat of fentanyl mixed with meth, leading to significant declines in participating communities.

In a cluster-randomized trial of 67 communities, intervention communities showed a nonsignificant 8% lower overdose death rate and a significant 37% reduction in deaths involving opioids and psychostimulants other than cocaine. These results suggest that community-focused, data-driven interventions with communication campaigns may help reduce some opioid-involved polysubstance overdose deaths.

U.S. infant deaths rose 7% post-Roe v. Wade, with a 10% increase in deaths from congenital abnormalities, per JAMA Pediatrics study.